2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - 391-392
Optimal dose for haploidentical transplant<br />Better characterizing products for retroviral vector mutations<br />Association of CD39 expression on CAR T-cells with oxidative stress/lipid peroxidation<br />Characterizing CAR T-cells based on LymphoMAP archetype.<br />Optimizing conditions for potency of CAR NK Cells<br />Efficient base gene editing for SCD using the Prodigy
Technology and Procedures, Assays, Molecular Testing, Gene Editing, Treatment Considerations, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Biological Processes, Immune Mechanism, Metabolism, Diseases, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Lymphoid Malignancies, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, B Cell Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Patient-Reported Outcomes, Study Population, Human
PAPER

433 Defining the optimal peripheral blood graft cell dose for haploidentical transplantation with PTCy in AML: A study from the acute leukemia working party of the EBMT

Jaime Sanz, MD, PhD, Jacques-Emmanuel Galimard2, Raynier Devillier, PhD3, Mohamad Mohty, MD, PhD4, Fabio Ciceri5, Maija Itälä-Remes6, Hélène Labussière-Wallet7, Etienne Daguindau8, Edouard Forcade, MD, PhD9, Patrice Chevallier10, Regis Peffault De Latour, MD, PhD11, Martin Carre, MD12, Zafer Gulbas13, Hakan Ozdogu14, Amandine Charbonnier15, Sebastien Maury16, Cristina Castilla-Llorente, MD17, Giorgia Battipaglia18, Simona Piemontese19, Eolia Brissot, MD, PhD20
1 Hematology Department, Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, Valencia, Spain, Valencia, Spain
2 EBMTParis Study Unit, Paris, France
3 Programme de Transplantation & Therapie Cellulaire, Marseille, France
4 Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France
5 Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
6 Turku University Hospital, Turku, Finland
7 Centre Hospitalier Lyon Sud, Lyon, Spain
8 CHU Besancon Franche-Comte, Besancon, France
9 CHU Bordeaux, Hopital Haut-Leveque, Pessac, France
10 CHU Nantes, Nantes, France
11 Saint-Louis Hospital, BMT Unit, Université de Paris Cité, Paris, France
12 CHU Grenoble Alpes - Universite Grenoble Alpes, Grenoble, France
13 Anadolu Medical Center Hospital, Kocaeli, Turkey
14 Baskent University Hospital, Aldana, Turkey
15 University of Amiens: CHU Amiens, Amiens, France
16 Hôpital Henri Mondor, Creteil, France
17 Gustave Roussy Cancer Campus, Villejuif, France
18 Department of Clinical Medicine and Surgery, Division of Hematology, Federico II University of Naples, Naples, Italy
19 Hematology and Bone Marrow Transplant Unit, IRCCS San Raffaele Scientific Institute, Milano, Italy
20 Hôpital Saint-Antoine, Sorbonne University, INSERM UMRs 938, Paris, France

Introduction: Peripheral blood (PB) is the predominant graft source for haploidentical donor hematopoietic cell transplantation (HCT) using post-transplant cyclophosphamide (PTCy). However, the impact of the CD34⁺ cell dose in PB grafts on transplantation outcomes remains uncertain, with limited and conflicting evidence.

Methods: We retrospectively evaluated the impact of CD34⁺ cell dose in PB haploidentical grafts on transplantation outcomes in adults with acute myeloid leukemia in first (CR1) or second complete remission who underwent HCT with PTCy-based graft-versus-host disease (GVHD) prophylaxis. Patients with available data on graft cell dose were identified in the European Society for Blood and Marrow Transplantation registry.

Results: A total of 1007 patients were included. The median recipient age was 57 years (IQR, 43–65); 604 (60%) were male, 757 (75%) were transplanted in CR1, and 657 (71%) and 207 (22%) had intermediate- and high-risk cytogenetics, respectively. Reduced-intensity conditioning was used in 693 patients (69%). The median donor age was 37 years (IQR, 28–46); 364 donors (36%) were female, of whom 222 (22%) donated to male recipients, and 545 donors (54%) were cytomegalovirus-seropositive. The median CD34⁺ cell dose was 6.2 ×10⁶/kg recipient body weight (IQR, 5–8). The cumulative incidence of neutrophil recovery by day 60 was 97% (95% CI, 95–98), with a median time to engraftment of 18 days (IQR, 16–22). The cumulative incidence of platelet recovery by day 180 was 85% (95% CI, 83–87), with a median time to recovery of 21 days (range, 15–28). The 100-day cumulative incidence of grade II–IV and grade III–IV acute GVHD was 36% (95% CI, 33–39) and 14% (95% CI, 11–16), respectively. At 2 years, the cumulative incidence of chronic and moderate/severe/extensive chronic GVHD was 38% (95% CI, 35–41) and 10% (95% CI, 8–12), respectively. After a median follow-up of 38 months, the 2-year cumulative incidence of relapse and non-relapse mortality was 19% (95% CI, 17–22) and 18% (95% CI, 16–20), respectively, while leukemia-free survival (LFS) and overall survival (OS) was 63% (95% CI, 60–66) and 69% (95% CI, 66–72), respectively. Patients were then stratified into three groups according to CD34⁺ cell dose based on quartile-derived cutoffs (Q1 and Q3): low (<5 × 10⁶/kg), intermediate (5–8 × 10⁶/kg), and high (>8 × 10⁶/kg). In multivariable analysis, a low CD34⁺ cell dose was associated with delayed neutrophil recovery (HR 0.69, 95% CI 0.58–0.82), a higher risk of relapse (HR 1.43, 95% CI 1.03–1.98), inferior LFS (HR 1.32, 95% CI 1.04–1.67), and a trend toward inferior OS (HR 1.26, 95% CI 0.98–1.62) compared with the intermediate-dose group. In contrast, a high CD34⁺ cell dose was associated with faster neutrophil recovery (HR 1.48, 95% CI 1.23–1.79) but had no significant impact on other transplantation outcomes, except for a lower risk of grade II–IV acute GVHD (HR 0.74, 95% CI 0.55–0.99).

Conclusions: A low CD34⁺ cell dose (<5 × 10⁶/kg) in PB grafts from haploidentical donors was associated with delayed neutrophil engraftment, a higher risk of relapse, and inferior survival. In contrast, a CD34⁺ cell dose >8 × 10⁶/kg accelerated neutrophil engraftment without adversely affecting other transplantation outcomes. These findings support targeting a minimum CD34⁺ cell dose of 5 × 10⁶/kg recipient body weight during donor apheresis.

Jaime Sanz, MD, PhD: No relevant conflicts of interest to declare.